Search Results

You are looking at 281 - 290 of 2,910 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer

Donald A. Podoloff, Ranjana H. Advani, Craig Allred, Al B. Benson III, Elizabeth Brown, Harold J. Burstein, Robert W. Carlson, R. Edward Coleman, Myron S. Czuczman, Dominique Delbeke, Stephen B. Edge, David S. Ettinger, Frederic W. Grannis Jr., Bruce E. Hillner, John M. Hoffman, Krystyna Kiel, Ritsuko Komaki, Steven M. Larson, David A. Mankoff, Kenneth E. Rosenzweig, John M. Skibber, Joachim Yahalom, JQ Michael Yu, and Andrew D. Zelenetz

any prior knowledge of the results of other studies is essential. Finally, assessing how the results of the PET scan impact patient management and improve health outcomes is important. Health outcomes include not only survival but also quality of life

Full access

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

Thomas Melchardt, Katharina Troppan, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Wolfgang Tränkenschuh, Konstantin Schlick, Florian Huemer, Alexander Deutsch, Peter Neumeister, Richard Greil, Martin Pichler, and Alexander Egle

with an independent and reproducible influence on the clinical outcome may further improve the NCCN-IPI. Patients and Methods This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria (415

Full access

Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer

Gerald A. Soff

was given for at least 6 months and up to 12 months. 3 For the primary outcome measure—a composite of recurrent VTE or major bleeding during the 12 months after randomization—edoxaban proved to be noninferior to LMWH ( Figure 2 ). “The hazard ratios

Full access

Paraneoplastic Syndromes Associated With Small Cell Lung Cancer

Leena Gandhi and Bruce E. Johnson

with ectopic corticotropin production and small-cell lung cancer . J Clin Oncol 1992 ; 10 : 21 – 27 . 17. Delisle L Boyer MJ Warr D . Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and

Full access

Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis

Elliott K. Yee, Natalie G. Coburn, Laura E. Davis, Alyson L. Mahar, Victoria Zuk, Vaibhav Gupta, Ying Liu, Craig C. Earle, and Julie Hallet

outcomes for the majority of patients with noncurable disease is therefore crucial. Previous work has revealed underassessment and low treatment rates for pancreatic adenocarcinoma, with 35% of patients with advanced disease not seeing a medical oncologist

Full access

High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex

Zheng Zhou, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael M. Millenson, Andrew D. Zelenetz, Joyce Niland, Jonathan W. Friedberg, and Jane N. Winter

Background Results of prospective clinical trials for patients with previously untreated diffuse large B-cell lymphoma (DLBCL) suggest that patient sex, weight, and/or body mass index (BMI) impact clinical outcomes. Recent reports implicate

Full access

Volume 19 (2021): Issue Suppl_1 (Nov 2021): The Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

Full access

CLO20-050: Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer

Jordan McDonald, Rutika Mehta, Sarah Hoffe, and Jose Pimiento

Full access

CLO19-034: The Clinical Outcomes of Next-Generation Sequencing Testing at a Community Oncology Practice

Christie Hancock and Jacob Bitran

Background: The value of next-generation sequencing (NGS) tests is dependent on how it changes clinical management, if at all. There are not any guidelines on when a physician should obtain testing; what certain genetic variations can be clinically, meaningfully intervened on; and if this active drug is financially practical. A NGS test ideally should identify a targetable mutational profile that leads to a treatment that can be obtained and produces lasting responses. We reviewed the NGS testing practices at our community hospital. Methods: Patients in our oncology clinic that underwent NGS testing of their tumor were reviewed. Specifically, the patient’s age, gender, diagnosis, date of diagnosis, previous lines of treatment, date of NGS testing, and reported molecular targets were recorded. Details of the changes in clinical management based on the NGS and survival time after the NGS test was ordered were also analyzed. Results: Forty-three patient cases were reviewed that had NGS testing obtained between the years 2014–2015 and 2017. Eighteen patients were males and 25 were females. Median age was 60 years. Most common tumor type was breast; 3 were triple-negative and 6 were only hormone-receptor positive. Second most common type was colorectal. NGS changed management in 12 cases. Two patients were able to enter a clinical trial and the other 10 had therapeutic changes based on protein or mRNA overexpression. Median time of change in management to survival in these patients was 7 months. Thirty-seven patients died; overall time from ordering of test to death was 7 months. Overall time of ordering test to survival for all patients was 8 months. Conclusions: NGS gathers a significant amount of information of a patient’s cancer, but this information is difficult to interpret in the clinical setting. Twenty-eight percent of our patients had a change in treatment, but this did not translate into lasting responses compared to other patients. Furthermore, the responses that were seen may have not been related to the therapeutic interventions, but intrinsic tumor biology. It is important to be aware of the clinical utility in ordering these tests for both the physician and patient.

Full access

Counterpoint: The Case for Immediate Active Treatment

Stacy Loeb and William J. Catalona

of nonpalpable prostate cancer with curative intent: preliminary results . J Urol 2002 ; 167 : 1231 – 1234 . 8. Warlick C Trock BJ Landis P . Delayed versus immediate surgical intervention and prostate cancer outcome . J Natl Cancer